ERRATUM

Erratum to: Anesthetic Selection and Disease-Free Survival Following Optimal Primary Cytoreductive Surgery for Stage III Epithelial Ovarian Cancer

Kevin M. Elias, MD^{1,2,3,4,5}, Stephanie Kang, BS², Xiaoxia Liu, MS², Neil S. Horowitz, MD^{1,4,5}, Ross S. Berkowitz, MD^{1,4,5}, and Gyorgy Frendl, MD, PhD, FCCM^{2,3,5}

¹Division of Gynecologic Oncology, Department of Obstetrics and Gynecology and Reproductive Biology, Brigham and Women's Hospital, Boston, MA; ²Surgical ICU Translational Research Center, Brigham and Women's Hospital, Boston, MA; ³Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital, Boston, MA; ⁴Dana-Farber Cancer Institute, Boston, MA; ⁵Harvard Medical School, Boston, MA

ERRATUM TO: ANN SURG ONCOL (2015) 22:1341–1348 DOI 10.1245/S10434-014-4112-9

Table 2 in the original article contains an error. In the study, 184/194 (95 %) patients received volatile anesthetics, whereas 10/194 (5 %) patients received total IV general anesthesia. These proportions are inverted in the original table. The proportions are stated correctly in the original text. Following is the corrected table:

TABLE 2 Treatment-related factors

Factor	<i>n</i> = 194	
Epidural analgesia, <i>n</i> (%)		
No	134	(61 %)
Yes	60	(39 %)
Type of general anesthesia		
Volatile anesthetics	184	(95 %)
Total IV general anesthesia	10	(5 %)
Volatile anesthetic used, <i>n</i> (%)		
Desflurane	30	(15 %)
Sevoflurane	137	(71 %)
Other	17	(9 %)
None	10	(5 %)
Level of surgical debulking, <i>n</i> (%)		

The online version of the original article can be found under doi:[10.1245/s10434-014-4112-9](https://doi.org/10.1245/s10434-014-4112-9).

© Society of Surgical Oncology 2015

Published Online: 28 March 2015

K. M. Elias, MD
e-mail: k Elias1@partners.org

TABLE 2 continued

Factor	<i>n</i> = 194	
No residual disease	67	(35 %)
Less than 0.5-cm residual disease	101	(52 %)
Less than 1-cm residual disease	26	(13 %)
Surgical complexity score, <i>n</i> (%)		
Low (≤ 6)	114	(59 %)
Medium (7–10)	74	(38 %)
High (> 10)	6	(3 %)
Estimated blood loss (ml), median (Q1,Q3)	500.0	(300.0, 1000.0)
Length of case (h), median (Q1,Q3)	3.1	(2.7, 3.9)
Length of hospital stay, median (Q1,Q3)	5.0	(4.0, 7.0)
RBC transfusion during admission, <i>n</i> (%)		
No	125	(64 %)
Yes	69	(36 %)
FFP, transfusion, <i>n</i> (%)		
No	165	(85 %)
Yes	29	(15 %)
Platelet transfusion, <i>n</i> (%)		
No	194	(100 %)
Yes	0	(0 %)
Type of first-line chemotherapy, <i>n</i> (%)		
IV carboplatin alone	5	(3 %)
IV carboplatin and IV gemcitabine	1	(1 %)
IV carboplatin and IV paclitaxel	92	(47 %)
IV carboplatin and IV paclitaxel and bevacizumab	23	(12 %)
IV paclitaxel and IP cisplatin/paclitaxel	69	(36 %)
None	1	(1 %)
Other	3	(2 %)
Total cycles of primary chemotherapy, median (Q1, Q3)	6.0	(5.0, 6.0)